Spots Global Cancer Trial Database for recurrent laryngeal cancer
Every month we try and update this database with for recurrent laryngeal cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer | NCT00004256 | Head and Neck C... Oral Complicati... Radiation Toxic... | sargramostim quality-of-life... radiation thera... | 20 Years - 80 Years | National Cancer Institute (NCI) | |
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer | NCT00004097 | Head and Neck C... | fluorouracil gemcitabine hyd... paclitaxel radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer | NCT00003777 | Head and Neck C... | amifostine trih... cisplatin fluorouracil surgical proced... radiation thera... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma | NCT00004261 | Breast Cancer Cervical Cancer Head and Neck C... Prostate Cancer Sarcoma | EF5 flow cytometry fluorescent ant... immunohistochem... biopsy | 18 Years - 120 Years | University Health Network, Toronto | |
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer | NCT00003251 | Drug/Agent Toxi... Head and Neck C... Radiation Toxic... | amifostine trih... cisplatin paclitaxel radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
Nomograms to Precisely Predict Conditional Risk of Recurrence for Patients With Laryngeal Cancer | NCT03595410 | Recurrent Laryn... | Recurrence lary... | 18 Years - 75 Years | First Affiliated Hospital, Sun Yat-Sen University | |
Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer | NCT00003327 | Head and Neck C... | paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors | NCT00003430 | Head and Neck C... Unspecified Adu... | L-778,123 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors | NCT01172028 | Breast Cancer Esophageal Canc... Gastric Cancer Head and Neck C... Lung Cancer Ovarian Cancer Prostate Cancer | Taxotere (Docet... Alimta (Pemetre... | 18 Years - | University of Arizona | |
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | NCT01806675 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Male Breast Can... Metastatic Squa... Recurrent Adeno... Recurrent Adult... Recurrent Basal... Recurrent Colon... Recurrent Esthe... Recurrent Hypop... Recurrent Inver... Recurrent Laryn... Recurrent Lip a... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Nasop... Recurrent Non-s... Recurrent Oroph... Recurrent Pancr... Recurrent Paran... Recurrent Recta... Recurrent Renal... Recurrent Saliv... Stage IIIA Brea... Stage IIIA Non-... Stage IIIB Brea... Stage IIIB Non-... Stage IIIC Brea... Stage IV Breast... Stage IV Non-sm... Stage IV Pancre... Stage IV Renal ... Stage IVA Colon... Stage IVA Recta... Stage IVA Saliv... Stage IVB Colon... Stage IVB Saliv... Stage IVC Saliv... Tongue Cancer Unspecified Adu... | 18F-fludeoxyglu... 18F-FPPRGD2 | 18 Years - | Stanford University | |
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors | NCT01172028 | Breast Cancer Esophageal Canc... Gastric Cancer Head and Neck C... Lung Cancer Ovarian Cancer Prostate Cancer | Taxotere (Docet... Alimta (Pemetre... | 18 Years - | University of Arizona | |
EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma | NCT00004261 | Breast Cancer Cervical Cancer Head and Neck C... Prostate Cancer Sarcoma | EF5 flow cytometry fluorescent ant... immunohistochem... biopsy | 18 Years - 120 Years | University Health Network, Toronto | |
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors | NCT00003430 | Head and Neck C... Unspecified Adu... | L-778,123 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck | NCT00003182 | Head and Neck C... | cisplatin gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors | NCT00499291 | Cancer | paclitaxel albu... gene expression... laboratory biom... pharmacological... polymerase chai... | 18 Years - 120 Years | Eastern Cooperative Oncology Group |